The Stable State is not an Objective Response in Hormone‐escaped Carcinoma of Prostate
- 1 December 1984
- journal article
- research article
- Published by Wiley in British Journal of Urology
- Vol. 56 (6) , 702-705
- https://doi.org/10.1111/j.1464-410x.1984.tb06151.x
Abstract
In some clinical trials the use of criteria of stable response of hormone-escaped prostate cancer is justified on the ground that it delineates patients with markedly improved survival, similar to that of partial regression patients. Patients (43) with hormone-escaped prostate cancer were studied in order to identify other factors which might also predict improved survival. Patients (15) received palliative treatment only, 17 secondary hormone therapy and 11 chemotherapy. Only 1 objective partial regression was seen. Patients (37) have died of prostatic cancer, 3 have died of other causes and 3 remain alive. The mean initial hormone response was 14.8 mo., the mean time from progression to death 11.3 mo. and the mean time from symptoms to death 5.9 mo. There was no significant correlation between length of initial responses and survival following progression (r = 0.25). Six features of progression were reviewed. Patients presenting with 1 feature of progression had a significantly better mean survival, 14.8 mo., compared with 8.2 mo. when multiple features indicated progression. The stable state is not an objective responses in hormone-escaped carcinoma of prostate but a reflection of the patient''s natural disease progression and that the mode of presentation may be a significant prognostic indicator.This publication has 9 references indexed in Scilit:
- SURVIVAL OF PATIENTS WITH METASTATIC CANCER OF THE PROSTATE AFTER REFERRAL TO MEDICAL ONCOLOGY UNITThe Lancet, 1984
- A Comparison of Estramustine Phosphate Versus Cis-platinum Alone Versus Estramustine Phosphate Plus Cis-platinum in Patients with Advanced Hormone Refractory Prostate Cancer Who Had Had Extensive Irradiation to the Pelvis or Lumbosacral AreaJournal of Urology, 1983
- A comparative clinical trial of adriamycin and 5‐fluorouracil in advanced prostatic cancer: Prognostic factors and responseThe Prostate, 1983
- Chemotherapy of Cancer of the ProstatePublished by Springer Nature ,1982
- The evaluation of a new enzyme immunoassay for the measurement of prostatic acid phosphataseClinica Chimica Acta; International Journal of Clinical Chemistry, 1981
- The importance of the stable category for chemotherapy treated patients with advanced and relapsing prostate cancerCancer, 1980
- Response criteria for the prostate of the USA national prostatic cancer projectThe Prostate, 1980
- Cyclophosphamide (NSC 26271) versus the combination of adriamycin (NSC 123127), 5-fluorouracil (NSC 19893), and cyclophosphamide in the treatment of metastatic prostatic cancer. A randomized trialCancer, 1978
- The Treatment of Oestrogen-Escaped Carcionoma of the Prostate with Estramustine PhosphateBritish Journal of Urology, 1977